Research programme: fusion protein therapeutics - Altor BioScience

Drug Profile

Research programme: fusion protein therapeutics - Altor BioScience

Alternative Names: 264scTCR/IgG1; ALT-802; ALT-804; Antiviral TCR - Ab; Antiviral TCR - Ck; IMPACT™ fusion proteins research programme - Altor BioScience; STAR-based therapeutics research programme - Altor BioScience; STAR-IMPACT; T cell receptor IgG1 fusion protein; T cell receptor IL-2 fusion protein

Latest Information Update: 21 Nov 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Altor BioScience Corporation; Massachusetts General Hospital
  • Class Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; Immunostimulants; Interleukin 15 receptor antagonists; Interleukin-15 receptor agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus; Viral infections

Most Recent Events

  • 20 Nov 2013 A lead candidate from this programme, ALT 803, has entered clinical development
  • 19 Jan 2011 Research programme: therapeutics - Altor BioScience is available for licensing as of 19 Jan 2011.
  • 05 Sep 2006 This programme is still in active development for cancer, viral infections, and autoimmune disorders, including rheumatoid arthritis, multiple sclerosis and type 1 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top